Novo Nordisk to launch new insulin Friday

Novo Nordisk will launch Ryzodeg—an insulin for type 2 diabetic patients—in Bangladesh on April 24.
Ryzodeg is a simple regimen with fewer injections than basal-bolus therapy that provides successful reduction of blood glucose with less chances of hypoglycaemia compared to conventional insulins, said A Rajan Kumar, managing director Novo Nordisk Pharma (Pvt) Ltd.
People with diabetes currently using basal-bolus regimens may need to take up to four daily injections, which can be inconvenient and stressful, the Danish pharmaceutical giant quoted Kumar as saying in a statement.
“Ryzodeg requires only two injections daily.”
Novo Nordisk, the global leader in diabetes care, has always been striving to develop products that address key challenges faced by people with diabetes and physicians, he said.
Ryzodeg is a combination of two distinct insulin analogues, degludec and aspart with ratio of 70:30, making it the first true combination of a basal insulin with an ultra-long duration of action and a well-established mealtime insulin in one pen, he said.
“We are serving Bangladesh with world class insulins for more than 50 years.” 
In a country like Bangladesh where diabetes has become one of the biggest healthcare challenges, it is critical that product innovations are aimed at assisting physicians to provide better and effective treatment options, he said.